메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

'김갑성' 기자의 전체기사

Iridium and Qualcomm Join Forces to Enable Satellite Connec…

Multiple Iridium data services integrated into the powerful Snapdragon platform for U.S. government and allied users MCLEAN, Va., Oct. 14, 2025 -- Iridium Communications Inc. (NASDAQ: IRDM), a leading provider of global voice, data, and PNT satellite services, and Qualcomm Technologies, Inc. (QTI) today announced that they have successfully integrated Iridium® data services into the Snapdragon® Mission Tactical Radio (MTR) and intend to make these services available for adoption and use by U.S. government customers and approved allied partners. By integra
- 김갑성 기자
- 2025-10-14 19:01
Clover Announces Positive Phase I Clinical Data for RSV-hMPV-…

-- Results indicate potential best-in-class RSV+hMPV±PIV3 combination vaccines, with the potential ability to re-vaccinate individuals previously receiving approved RSV vaccines to restore and broaden protection -- -- Increases in neutralizing antibodies of approximately 6-8 fold for RSV, 6-9 fold for hMPV and 4 fold for PIV3 (≥10 fold increases in PIV3 PreF-specific antibodies) were observed -- -- Interim analysis from RSV re-vaccination trial demonstrates ≥60% higher trend in RSV neutralizing antibodies for Clover's RSV vaccine compared head-to-head versus AREXVY (GSK) i
- 김갑성 기자
- 2025-10-14 18:18
Infosys Chosen by NHSBSA to Deliver a New Workforce Manage…

Next-Generation solution supports the NHS 10-year Health Plan and the mission to create a workforce that is fit for the future LONDON and BENGALURU, India, Oct. 14, 2025 -- Infosys (NSE: INFY) (BSE: INFY) (NYSE: INFY), a global leader in next-generation digital services and consulting, today announced that it has been awarded a £1.2 billion, 15-year contract by the NHS Business Services Authority (NHSBSA) to deliver the Future NHS Workforce Solution. Infosys will develop a cutting-edge, data-driven workforce management solution that will replace the current Electronic Sta
- 김갑성 기자
- 2025-10-14 18:02
Ascletis Completes Denifanstat (ASC40) Pre-NDA Consultation w…

[ 메디채널 김갑성 기자 ] - Denifanstat (ASC40) met all primary, key secondary and secondary efficacy endpoints (ITT analysis) and significantly improved moderate-to-severe acne vulgaris compared with placebo in a Phase III randomized, double-blind, placebo-controlled, multicenter clinical trial. HONG KONG, Oct. 14, 2025 -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that it recently completed the pre-New Drug Application (NDA) consultation with China National Medical Products Administration (NMPA) for denifanstat (ASC40) for the treatment of moderate-to-severe acne
- 김갑성 기자
- 2025-10-14 18:00
Kyoto University Engineering Ph.D. Team Realizes Achieveme…

[ 메디채널 김갑성 기자 ] —— Globally Pioneering POGMENT Triple-Helix Biomimetic Collagen Debuts at Chinese Biomaterials Congress 2025 CHENGDU, China, Oct. 14, 2025 -- The 2025 Chinese Biomaterials Congress was recently held in Shaoxing, Zhejiang, gathering leading experts including academicians from the Chinese Academy of Engineering and the Chinese Academy of Sciences, together with international figures such as U.S. National Academy of Engineering member Leonard Pinchuk, UK Royal Society Fellow Molly Stevens, and Professor Kunio Ishikawa, President of the Japanese Society for Biomaterials.&
- 김갑성 기자
- 2025-10-14 17:22
Telix Reports US$206M Revenue, FY 2025 Guidance Upgraded

MELBOURNE, Australia and INDIANAPOLIS, Oct. 14, 2025 -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today provides an update on its commercial and operational performance for the quarter ended 30 September 2025 (Q3 2025). All figures are in USD unless stated otherwise. Q3 2025 Highlights Q3 2025 unaudited group revenue of approximately $206 million, up 53% year-over-year. FY 2025 revenue guidance increased to $800 million to $820 million[1]. Gozellix® now fully reimbursed by Centers for Medicare and Medicaid Services
- 김갑성 기자
- 2025-10-14 14:59
Great Novel Therapeutics Biotech & Medicals Corporation (G…

TAIPEI, Oct. 14, 2025 -- GNTbm (stock code: 7427, Taiwan) announced the preclinical data on GNTbm-TKI, a novel multi-receptor tyrosine kinase inhibitor for cancer immunotherapy. GNTbm-TKI will be presented as posters at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting, which is held in Berlin, Germany, from Oct 17 to 21, 2025. Abstract: 2242Title: Preclinical development of GNTbm-TKI, a novel multi-receptor tyrosine kinase inhibitor, while combined with GNTbm-38 showing potent induced tumor microenvironment remodeling activity in cancer immunotherapySession Date/Tim
- 김갑성 기자
- 2025-10-14 14:26
2025 ACR Abstract Released! Exciting Data from Telitacicept's P…

In the results of China Phase III clinical trial announced at the 2025 ACR, Telitacicept demonstrated statistically significant and clinically meaningful improvements in ESSDAI [EULAR (European League Against Rheumatism) Sjögren's Syndrome Disease Activity Index] compared to placebo. Telitacicept met the primary endpoint and all key secondary endpoints. Patients in Telitacicept groups showed significant improvement in disease activity compared to the placebo group. Approximately 71.8% of patients receiving Telitacicept 160mg achieved an ESSDAI reduction of ≥3 points at 24 w
- 김갑성 기자
- 2025-10-14 13:44
Everest Medicines Announces First Patient Enrolled in a Glob…

SHANGHAI, Oct. 14, 2025 -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that the first patient has been enrolled in a global multi-center Phase I clinical trial of its Tumor-Associated Antigen Cancer Vaccine EVM14 at NEXT Oncology Virginia in the United States. This marks an important clinical achievement following EVM14's Investigational New Drug (IND) approvals by both the U.S. Food and Drug Adminis
- 김갑성 기자
- 2025-10-14 12:13
제138회 중국수출입박람회, 10월 15일 광저우에서 개장

[ 메디채널 김갑성 기자 ] 광저우, 중국 2025년 10월 14일 -- 흔히 캔톤페어(Canton Fair)라고 불리는 제138회 중국수출입박람회(China Import and Export Fair)가 광저우에서 10월 15일부터 11월 4일까지 3단계로 나뉘어 진행된다. 캔톤페어는 전시장과 별도로 전 세계 바이어들이 언제 어디서든 중국 제조업체와 상담할 수 있도록 24시간 내내 온라인 운영 상태를 유지한다. 155만 제곱미터의 전시 면적에 7만 4600개의 부스가 마련되고 참가 기업이 3만 2000개를 넘을 정도로 이번 박람회는 역대 최대 규모를 자랑한다. 제138회 중국수출입박람회는 규모뿐 아니라 혁신 면에서도 기념비적인 행사이다. 사상 처음으로, '중국 첨단 기술 회사(National High-Tech Enterprise)', '전문화/고도화 중소기업(Specialized and Sophisticated SME)', '1위 제조회사(Manufacturing Single Champion)' 등 중국 정부에서 지정한 칭호를 획득한 수출 회사 중 34%에 해당하는 1만 개 이상의 기업이 캔톤페어에 참가한다. 다양하게 마련된
- 김갑성 기자
- 2025-10-14 09:28

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2025-10-19_SUN

2025-10-18_SAT

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 10월 19일 03시 20분